Drug Profile
FCX 013
Alternative Names: FCX-013Latest Information Update: 08 Jul 2022
Price :
$50
*
At a glance
- Originator Fibrocell Science
- Developer Fibrocell Science; Precigen Inc
- Class Cell therapies; Fibroblast cell therapies; Gene therapies; Skin disorder therapies
- Mechanism of Action Gene transference; Matrix metalloproteinase 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Circumscribed scleroderma
Most Recent Events
- 24 Jun 2022 Castle Creek Biosciences terminates a phase I/II trial in Circumscribed scleroderma in US due to their own decision (NCT03740724)
- 23 Mar 2021 Phase-I/II development is ongoing in Circumscribed scleroderma in USA (Intradermal)
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc